MolMed Receives Green Light for Phase 1/2 Trial to Test CAR T-cell Therapy in Myeloma, Leukemia Patients
The Italian Medicines Agency has approved a first-in-human clinical trial testing MolMed’s investigational CAR T-cell product, CD44v6, for the treatment of acute myeloid…